Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences, Inc.

https://www.neurocrine.com/

Latest From Neurocrine Biosciences, Inc.

Early Promise From Axovant’s Parkinson’s Gene Therapy

Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.

Commercial Clinical Trials

Finance Watch: Two New VC Funds Raise $755m To Fund Innovation

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.

Financing StartUps and SMEs

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Clinical Trials Business Strategies

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Ophthalmic M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register